TSXV - Delayed Quote CAD
Waverley Pharma Inc. (WAVE.V)
At close: October 15 at 1:36 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
293.4040
412.0900
1,246.8320
1,752.8480
1,375.1050
--
Cost of Revenue
215.4200
332.2890
963.0430
1,530.1790
1,193.3990
--
Gross Profit
77.9840
79.8010
283.7890
222.6690
181.7060
--
Operating Expense
1,212.1800
1,313.6850
921.9450
1,009.4950
891.3070
--
Operating Income
-1,134.1960
-1,233.8840
-638.1560
-786.8260
-709.6010
--
Net Non Operating Interest Income Expense
-97.3770
-76.6530
-16.6380
-3.0370
5.3920
--
Other Income Expense
-917.0430
-913.5110
-9.2820
-6.6440
-1.5540
--
Pretax Income
-2,148.6160
-2,224.0480
-664.0760
-796.5070
-705.7630
--
Net Income Common Stockholders
-2,148.6160
-2,224.0480
-664.0760
-796.5070
-705.7630
--
Diluted NI Available to Com Stockholders
-2,148.6160
-2,224.0480
-664.0760
-796.5070
-705.7630
--
Basic EPS
-0.03
-0.04
-0.01
-0.01
-0.01
--
Diluted EPS
-0.03
-0.04
-0.01
-0.01
-0.01
--
Basic Average Shares
54,000.0000
54,000.0000
54,000.0000
54,000.0000
54,000.0000
--
Diluted Average Shares
54,000.0000
54,000.0000
54,000.0000
54,000.0000
54,000.0000
--
Total Expenses
1,427.6000
1,645.9740
1,884.9880
2,539.6740
2,084.7060
--
Net Income from Continuing & Discontinued Operation
-2,148.6160
-2,224.0480
-664.0760
-796.5070
-705.7630
--
Normalized Income
-1,201.8830
-1,280.8470
-654.7940
-747.8860
-692.4280
--
Interest Income
--
--
--
--
5.3920
45.9930
Net Interest Income
-97.3770
-76.6530
-16.6380
-3.0370
5.3920
--
EBIT
-1,137.7280
-1,233.8840
-638.1560
-786.8260
-709.6010
--
EBITDA
-896.2990
-911.9790
-530.4310
-758.6600
-701.4290
--
Reconciled Cost of Revenue
215.4200
332.2890
963.0430
1,530.1790
1,193.3990
--
Reconciled Depreciation
241.4290
321.9050
107.7250
28.1660
8.1720
--
Net Income from Continuing Operation Net Minority Interest
-2,148.6160
-2,224.0480
-664.0760
-796.5070
-705.7630
--
Total Unusual Items Excluding Goodwill
-946.7330
-943.2010
-9.2820
-48.6210
-13.3350
--
Total Unusual Items
-946.7330
-943.2010
-9.2820
-48.6210
-13.3350
--
Normalized EBITDA
50.4340
31.2220
-521.1490
-710.0390
-688.0940
--
12/31/2019 - 10/27/2017
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
IOT.V Innovotech Inc.
0.1350
0.00%
TELI.CN Telescope Innovations Corp.
0.4500
+12.50%
CVALF Covalon Technologies Ltd.
2.2700
+1.79%
COV.V Covalon Technologies Ltd.
3.1400
-1.26%
MLEC Moolec Science SA
0.8500
-4.49%
CNSP CNS Pharmaceuticals, Inc.
0.1220
+1.84%
GANX Gain Therapeutics, Inc.
2.7000
-2.53%
TNYA Tenaya Therapeutics, Inc.
2.0400
-5.12%
RNAZ TransCode Therapeutics, Inc.
0.6131
+2.35%
EXAI Exscientia plc
5.21
+2.96%